Thioether-substituted galactopyranoside derivative, preparation method therefor, and use thereof
By developing thioether-substituted galactopyranoside derivatives that specifically bind to Gal-3, the problem of insufficient inhibition of Gal-3 activity in existing technologies has been solved, enabling effective treatment of fibrotic diseases, tumors, and inflammatory diseases.
WO2026086940A1PCT designated stage Publication Date: 2026-04-30SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/129940
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-13
- Filing Date
- 2025-10-24
- Publication Date
- 2026-04-30
AI Technical Summary
Technical Problem
Existing technologies are unable to effectively inhibit galactolectin-3 (Gal-3) activity, resulting in poor treatment outcomes for fibrotic diseases, tumor progression, and inflammatory diseases.
Method used
A class of thioether-substituted galactopyranoside derivatives were developed that regulate related biological processes by specifically binding to Gal-3 and inhibiting its activity.
Benefits of technology
It effectively inhibits Gal-3 activity and has the potential to treat fibrotic diseases, tumors, nervous system diseases, and inflammatory diseases, providing a new treatment approach.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2025129940_30042026_PF_FP_ABST
Abstract
Disclosed in the present invention are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. Specifically, disclosed in the present invention are a thioether-substituted galactopyranoside derivative, a preparation method therefor, and a use thereof.
Need to check novelty before this filing date? Find Prior Art